# Ackermans & van Haaren

> Ackermans & van Haaren is a VC fund backing Health Care and Medical. See 18 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Antwerpen, Belgium
- Total investments: 18
- Last investment: May 2026
- Lead investor: 39%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/ackermans-&-van-haaren
- Website: https://www.avh.be/

Ackermans & van Haaren is a diversified group active in 5 segments: Marine Engineering & Infrastructure; Private Banking; Real Estate, Leisure & Senior Care; Energy & Resources; Development Capital. Marine Engineering & Infrastructure: DEME, one of the largest dredging companies in the world - Algemene Aannemingen Van Laere,a leading contractor in Belgium. Ackermans & van Haaren is an independent and diversified group aiming at creating shareholder value through long-term investments in a limited number of companies with growth potential on an international level.

## Contacts

5 contacts available for Ackermans & van Haaren. Shizune tracks 6 team members at Ackermans & van Haaren. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ackermans-van-haaren?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $30M–$42M |
| Series A | $8.4M–$15M |
| Series B | $3.4M–$72M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 28% |
| Medical | 4 | 22% |
| Biotechnology | 4 | 22% |
| Pharmaceutical | 3 | 17% |
| Therapeutics | 2 | 11% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 33% |
| Seed | 2 | 11% |
| Series A | 2 | 11% |
| Series C | 2 | 11% |
| Series D | 1 | 6% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 6 | 33% |
| India | 1 | 6% |
| Germany | 1 | 6% |
| The Netherlands | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jeroen Vangindertael | Investment Manager | 2 | https://shizune.co/investors/profile/jeroen-vangindertael |
| Luc Bertrand | CEO | 0 | https://shizune.co/investors/profile/luc-bertrand |
| Matthias De Raeymaeker | Investment manager | 0 | https://shizune.co/investors/profile/matthias-de-raeymaeker |
| Philip Heylen | Business Development Manager | 0 | https://shizune.co/investors/profile/philip-heylen |
| Pierre Macharis | Non Executive Director | 0 | https://shizune.co/investors/profile/pierre-macharis |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Biotalys | Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium. | $14.1M | Post-IPO Equity | May 06, 2026 |  |
| DISCO Pharmaceuticals | DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells. | $42.3M | Seed | Dec 11, 2025 |  |
| MRM Health NV | MRM Health NV, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with the Flemish Institute ofBiotechnology (VIB), an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications. | $64.1M | Series B | Sep 04, 2025 |  |
| Biotalys | Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium. | $16.4M | Post-IPO Equity | Oct 14, 2024 |  |
| Confo Therapeutics | Confo Therapeutics is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. Confo Therapeutics employs its proprietary CONFO technology to lock inherent unstable functional conformations of GPCRs as a superior starting point for drug discovery. CONFO body-stabilized active state conformations ofthese receptors disclose previously inaccessible structural features empowering the discovery of novel agonists for better therapeutic intervention. | $65.2M | Series B | Jul 26, 2024 |  |
| Vico Therapeutics | Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands. | $12.3M | Series B | Jun 24, 2024 |  |
| Vico Therapeutics | Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands. | $72.1M | Series B | Jan 05, 2024 |  |
| Vico Therapeutics | Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands. | $72.1M | Series B | Jan 05, 2024 |  |
| AstriVax | AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline. | $29.9M | Seed | Aug 25, 2022 |  |
| Medikabazaar | Medikabazaar is an online B2B marketspace for medical supplies and equipment. The company is a single point of contact for all product-based needs, enabling medical institutions and individual practitioners alike to cut down on operational costs and making the best global brands available locally, all aided with the miracle that goes by the name oftechnology. Medikabazaar is connected with more than 50,000 medical establishments, 1,50,000 Independent Practitioners, and have partnered with 13,000+ suppliers all over India including ones in Tier 2, Tier 3 cities, and remoter locations to establish a strong foothold in India.With the power of technology, Medikabazaar organized a haywire market in a country with perhaps the largest and most complex geographical structure in the world for this purpose. Medikabazaar's last-mile delivery system and 26 strategically placed Fulfilment Centers across India enable the company to deliver essential medical supplies to healthcare facilities and help them nurture quality and timely patient care. | $64.9M | Series D | Apr 12, 2022 |  |

10 of 18 investments shown.

## Co-investors
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 8 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 5 deals together
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund, 4 deals together
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund, 4 deals together
- [VIB](https://shizune.co/investors/profile/vib) — VC Fund, 4 deals together
- [Droia Ventures](https://shizune.co/investors/profile/droia) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)
- [Health Care VC Funds in Belgium](https://shizune.co/investors/health-care-vc-funds-belgium)
- [Biotechnology VC Funds in Belgium](https://shizune.co/investors/biotechnology-vc-funds-belgium)
- [Biotech Investors in Belgium](https://shizune.co/investors/biotech-investors-belgium)
- [Biotech VC Funds in Belgium](https://shizune.co/investors/biotech-vc-funds-belgium)
- [Medical VC Funds in Belgium](https://shizune.co/investors/medical-vc-funds-belgium)

## FAQ

### What does Ackermans & van Haaren invest in?

Ackermans & van Haaren invests primarily in Health Care, Medical and Biotechnology startups, most often at Series B and Seed stage. Most of the 18 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Ackermans & van Haaren's check size?

Ackermans & van Haaren typically joins rounds of $30M–$42M at Seed, $8.4M–$15M at Series A and $3.4M–$72M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ackermans & van Haaren participates in.

### How do I contact Ackermans & van Haaren?

Public channels for Ackermans & van Haaren include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Ackermans & van Haaren?

The team at Ackermans & van Haaren includes Jeroen Vangindertael (Investment Manager), Luc Bertrand (CEO) and Matthias De Raeymaeker (Investment manager), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co